Pfizer’s Phase 3 Study on Elranatamab: A Potential Game-Changer for Multiple Myeloma Treatment

Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.

Pfizer Inc. is conducting a Phase 3 clinical study titled ‘MagnetisMM-32’ to evaluate the efficacy of elranatamab in patients with relapsed or refractory multiple myeloma (MM). The study aims to compare elranatamab monotherapy against various combination therapies, including elotuzumab, pomalidomide, dexamethasone, bortezomib, and carfilzomib, in patients who have previously undergone anti-CD38 directed therapy. This research is significant as it seeks to provide new treatment options for MM patients whose cancer has returned or not responded to prior treatments.

The intervention being tested is elranatamab, a drug administered subcutaneously, intended to treat multiple myeloma by targeting specific cancer cells. The study also involves comparator treatments using combinations of existing drugs administered either orally, intravenously, or subcutaneously.

This interventional study employs a randomized, parallel assignment model with no masking, focusing primarily on treatment efficacy. Participants are divided into two groups: one receiving elranatamab and the other receiving a combination therapy chosen by the study doctor.

The study began on February 8, 2024, with an estimated completion date in 2025. The last update was submitted on June 23, 2025. These dates are crucial for tracking the study’s progress and anticipated results.

The outcome of this study could significantly impact Pfizer’s stock performance by potentially introducing a new treatment option in the competitive multiple myeloma market. Positive results may enhance investor confidence and position Pfizer favorably against competitors in the oncology sector.

The study is currently recruiting, with further details available on the ClinicalTrials portal.